Skip to main content
OpenTrials
Completed

NCT Number: NCT06849791

A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants

This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteer

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Acpru /Id# 266649

Grayslake, Illinois, 60030, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body Mass Index (BMI) ≥ 18.0 to ≤ 32.0 kg/m^2 after rounding to the tenths decimal at the time of screening and upon initial confinement. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG

Exclusion criteria

  • History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.

Treatment and study plan

ABBV-932

Drug

Oral Capsule

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of ABBV-932

    Time frame: Up to approximately 6 days

    Cmax of ABBV-932

  2. Time to Cmax (Tmax) of ABBV-932

    Time frame: Up to approximately 6 days

    Tmax of ABBV-932

  3. Terminal Phase Elimination Rate Constant (Beta) of ABBV-932

    Time frame: Up to approximately 6 days

    Terminal phase elimination rate constant (beta) of ABBV-932

  4. Terminal Phase Elimination Half-Life (t1/2) of ABBV-932

    Time frame: Up to approximately 6 days

    Terminal phase elimination half-life of ABBV-932

  5. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932

    Time frame: Up to approximately 6 days

    AUCt of ABBV-932

  6. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932

    Time frame: Up to approximately 6 days

    AUCinf of ABBV-932

  7. Number of Participants Experiencing Adverse Events

    Time frame: Up to approximately 180 days

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

Assessment of the Relative Bioavailability of ABBV-932 Formulations in Healthy Adult Subjects

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Feb 27, 2025
Registry last updated
Jun 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.